CG Oncology (CG Oncology) Non Operating Income : $-0.01 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Non Operating Income?

Non Operating Income is income or expense that comes from miscellaneous sources. CG Oncology's Non Operating Income for the three months ended in Mar. 2024 was $-0.01 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.01 Mil.

CG Oncology Non Operating Income Historical Data

The historical data trend for CG Oncology's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Non Operating Income Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Non Operating Income

0.22

-0.20

-0.06

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Non Operating Income	Get a 7-Day Free Trial			0.01	0.01	-	-	-0.01

CG Oncology Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

CG Oncology Non Operating Income Related Terms

Thank you for viewing the detailed overview of CG Oncology's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Non Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024